Compare Quest Diagnostics Inc (DGX) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Macy's Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Macy's Inc trades at $22.67 (market cap $5.95B). The key difference: Quest Diagnostics Inc is far larger — about 4.3× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Macy's Inc for 58 Days on average.
| DGX | M | |
|---|---|---|
Market Cap | $25.48B | $5.95B |
Volume | 941,866 | 6,030,644 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $26.21 |
52-Week Low | $173.49 | $16.51 |
Typical Hold Time | 56 Days | 58 Days |
Enterprise Value | $31.23B | $9.75B |
Dividend Yield | 1.49% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Macy's (M) trades at $22.67, down 0.53% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27, supported by a 15.99% ROE. Recent earnings have consistently beaten estimates, and the company's 'A Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has declined from 2022 peaks. Cash flow trends are improving, with net cash flow turning positive in 2024 and 2025.
The outlook is cautiously optimistic, with a consensus price target of $24.25 offering potential upside. Investment opportunities include deep value, dividend yield, and successful turnaround execution. Key risks are competitive pressures, uneven sales growth, and macroeconomic sensitivity affecting consumer spending. Analyst sentiment is mixed, with 32% buy ratings but 51% hold, reflecting uncertainty around sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
